Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease? - Wikidata - wikimedia - TriplyDB

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

http://www.wikidata.org/entity/Q55003026

about

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

http://www.wikidata.org/entity/Q55003026

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

@en

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

@nl

type

label

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

@en

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

@nl

prefLabel

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

@en

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

@nl

P1433

Q55003026-D8A15BEC-5431-41EF-A5E4-797A20F92E77

P1476

Q55003026-1A495ABC-05F9-4CF4-912E-46064BD52AD4

P2093

Q55003026-3684830B-16E7-4D61-8389-97D2A220027A

Q55003026-448F4724-381E-4C59-8E0A-E0D2B8DA77D0

Q55003026-51A4F43D-0076-43DF-AA2C-9733839FA9EE

Q55003026-81EC8041-64A6-41E2-8A1F-4165F3AB80F4

Q55003026-F51C95A6-AA81-44FA-99A3-B3FD6EE63FAD

P2860

Q55003026-07B3318C-77D6-4D0D-8D3C-2F7A318220C7

Q55003026-13DDFA29-9C87-4180-A095-AA8BD7E6C0D5

Q55003026-1AF35A5E-6E06-41B8-B16F-20DDAAEBBA36

Q55003026-2373C6B5-AE7C-4F3E-8CCD-22CE2B60674B

Q55003026-33269B0F-B11F-405C-A898-82627D789187

Q55003026-394440B2-EBAB-4E5A-ADD0-D34EC63683F0

Q55003026-4616CD36-8C9E-4196-B555-7613F13FFFAD

Q55003026-46681C5D-79E2-49E9-B54A-30EFF9B30792

Q55003026-47BB24CA-0C38-421D-BA6C-0EF55E1763EB

Q55003026-49ED50AF-6083-4301-95B1-42FAB6376412

P304

Q55003026-B655A215-3DFB-48B1-B32D-856993038CC7

P31

Q55003026-229EFC54-50D8-42CD-9306-2E4EEF173A39

P356

Q55003026-AFF84BD5-614C-42D9-A394-4AA5EDE5452E

P433

Q55003026-6A0FCE45-AB3C-45C5-BB41-211DB4DD75C8

P478

Q55003026-7FAA7547-0EAD-43D0-BC18-EDCECC85CBF8

P577

Q55003026-0769D31C-C988-4B60-BB09-2283600B9F6E

P698

Q55003026-4CFFCEE9-5A1D-4440-B454-234449A4F830

P921

Q55003026-4A658B44-4D04-4C57-B996-7D8799EE2E42

Q55003026-6C177654-2373-4C66-B3E1-08D4C97AC2A4

P932

Q55003026-ED56A208-77BD-4582-87B7-9C46F0F3C799

P356

P1433

World journal of nephrology

P1476

Is serum copeptin a modifiable biomarker in autosomal dominant polycystic kidney disease?

@en

P2093

Annette Wong

http://www.w3.org/2001/XMLSchema#string

Carly Mannix

http://www.w3.org/2001/XMLSchema#string

Gopala Rangan

http://www.w3.org/2001/XMLSchema#string

Jennifer Zhang

http://www.w3.org/2001/XMLSchema#string

Moomal Tasneem

http://www.w3.org/2001/XMLSchema#string

P2860

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

A painful inheritance-patient perspectives on living with polycystic kidney disease: thematic synthesis of qualitative research.

Comparison between siblings and twins supports a role for modifier genes in ADPKD.

Predictors of autosomal dominant polycystic kidney disease progression

Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.

Effect of increased water intake on plasma copeptin in patients with chronic kidney disease: results from a pilot randomised controlled trial.

Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort

Vasopressin directly regulates cyst growth in polycystic kidney disease.

Assessment of Diagnostic and Prognostic Role of Copeptin in the Clinical Setting of Sepsis

P304

51-57

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5527/WJN.V7.I2.51

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29527508

http://www.w3.org/2001/XMLSchema#string

P921

autosomal dominant polycystic kidney disease

P932

5838414

http://www.w3.org/2001/XMLSchema#string